3C-FP
Pharmaceutical compound
From Wikipedia, the free encyclopedia
3C-FP, also known as 4-(3-fluoropropoxy)-3,5-dimethoxyamphetamine or as α-methylfluoroproscaline (3C-fluoroproscaline), is a psychedelic drug of the phenethylamine, amphetamine, and 3C families related to TMA (3,4,5-TMA).[1][2][3][4] It is the amphetamine (α-methyl) derivative of fluoroproscaline (FP).[1][3][4]
- None
| |
| Clinical data | |
|---|---|
| Other names | 4-(3-Fluoropropoxy)-3,5-dimethoxyamphetamine; 3,5-Dimethoxy-4-(3-fluoropropoxy)amphetamine; α-Methylfluoroproscaline; 3C-Fluoroproscaline |
| Routes of administration | Oral[1] |
| Drug class | Serotonin receptor modulator; Serotonin 5-HT2A receptor agonist; Serotonergic psychedelic; Hallucinogen |
| ATC code |
|
| Pharmacokinetic data | |
| Duration of action | ~8 hours[1] |
| Identifiers | |
| |
| PubChem CID | |
| ChemSpider | |
| Chemical and physical data | |
| Formula | C14H22FNO3 |
| Molar mass | 271.332 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
According to Daniel Trachsel, 3C-FP's dose is 25 mg or more orally and its duration is approximately 8 hours.[1] The specific effects of 3C-FP were not described.[1]
The receptor interactions of 3C-FP have been studied.[4][3] It shows affinity for the serotonin 5-HT2A and 5-HT2C receptors (Ki = 2,600–4,581 nM and 4,400 nM) and is a potent partial agonist of the serotonin 5-HT2A receptor (EC50 = 57 nM; Emax = 62%) but not of the serotonin 5-HT2B receptor (EC50 = >10,000 nM).[4][3]
The chemical synthesis of 3C-FP has been described.[2]
3C-FP was first described in the scientific literature by Trachsel in 2002.[2] Subsequently, its pharmacology as well as its properties in humans were reported by Trachsel and colleagues in 2012,[3] 2013,[1] and 2021.[4]